GO:0004967 glucagon receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004967 (glucagon receptor activity) is a molecular function defined as combining with glucagon and transmitting the signal across the membrane by activating an associated G-protein, promoting GDP-for-GTP exchange on the G-alpha subunit [QuickGO definition].
• The glucagon receptor (GCGR) is a class B G-protein-coupled receptor that mediates glucagon-stimulated hepatic glucose production and is a validated drug target for diabetes and obesity.
• GCGR signaling is regulated by beta-arrestin recruitment and receptor internalization, with structural insights into arrestin tail engagement now available.
• Dysregulated glucagon receptor activity contributes to hyperglycemia, chronic kidney disease, and heart failure with preserved ejection fraction.
• Dual and triple receptor agonists (e.g., LY3437943, mazdutide) that engage GCGR alongside GIPR and GLP-1R show clinical benefit for glycemic control and weight loss.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of GCGR signaling in metabolic and cardiovascular disease.
Description
Glucagon receptor activity (GO:0004967) is a molecular function that mediates cellular responses to the pancreatic hormone glucagon. According to the QuickGO definition, this activity involves combining with glucagon and transmitting the signal across the membrane by activating an associated G-protein, promoting the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. The glucagon receptor (GCGR) is a class B G-protein-coupled receptor predominantly expressed in the liver, kidney, and other tissues, where it regulates glucose homeostasis and energy metabolism. Researchers study this activity to understand metabolic disease mechanisms and to develop therapeutics for diabetes, obesity, and cardiovascular conditions. Recent structural and pharmacological advances have clarified how GCGR engages G-proteins and arrestins, and how its activity can be modulated by small molecules and peptide agonists. This article synthesizes authoritative GO annotation and verified PubMed literature to provide a research-grade overview of glucagon receptor activity, its genes, regulation, disease links, and experimental models.
glucagon receptor activity At A Glance
| GO ID | GO:0004967 |
|---|---|
| GO term | glucagon receptor activity |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Combining with glucagon and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. |
| Major function | Glucagon binding and G-protein activation, leading to downstream signaling. |
| Representative gene | GCGR (glucagon receptor) |
| Cellular location | Plasma membrane |
| Pathway context | Class B GPCR signaling; adenylyl cyclase activation; cAMP production. |
What Is GO:0004967?
In our own words, GO:0004967 (glucagon receptor activity) is the function of a receptor that binds the hormone glucagon and, upon binding, activates an associated heterotrimeric G-protein by promoting the exchange of GDP for GTP on the G-alpha subunit. This activity transmits a signal across the cell membrane, initiating intracellular signaling cascades. It is a molecular function term in the Gene Ontology, distinct from the biological processes it regulates (e.g., glucose homeostasis) and the cellular components involved (e.g., plasma membrane).
Why Is glucagon receptor activity Important in Cell Biology?
Glucagon receptor activity is central to glucose homeostasis and is a validated therapeutic target for metabolic diseases. Dysregulated GCGR signaling contributes to hyperglycemia in diabetes, and pharmacological modulation of this activity can improve glycemic control and promote weight loss. Moreover, GCGR activity influences renal function and cardiovascular pathophysiology, making it relevant to chronic kidney disease and heart failure with preserved ejection fraction. Understanding the molecular details of glucagon receptor activity is therefore essential for developing targeted therapies and for interpreting genetic and pharmacological studies.
• Regulates hepatic glucose production and systemic glucose homeostasis.
• Validated target for diabetes and obesity therapies, including dual and triple agonists.
• Involved in chronic kidney disease progression via kidney GCGR downregulation.
• Contributes to heart failure with preserved ejection fraction pathophysiology.
• Constitutively active GCGR variants can drive hyperglycemia in birds, illustrating evolutionary and physiological importance.
• Natural product antagonists (e.g., dauricine) modulate GCGR activity, offering chemical probes.
• Arrestin-mediated regulation of GCGR affects signaling duration and receptor trafficking.
• CRISPR models enable causal testing of GCGR variants in metabolic and cardiovascular disease.
What Happens During glucagon receptor activity?
Glucagon binding and receptor activation
In simple terms: Glucagon binds to its receptor on the cell surface, switching the receptor on.
Glucagon receptor activity begins when the hormone glucagon binds to the extracellular domain of the glucagon receptor (GCGR), a class B G-protein-coupled receptor. This binding induces conformational changes that allow the receptor to act as a guanine nucleotide exchange factor for an associated heterotrimeric G-protein [QuickGO definition]. Structural studies have revealed how arrestin engages the receptor tail, which is important for desensitization and internalization.
G-protein activation and GDP/GTP exchange
In simple terms: The activated receptor turns on a G-protein by swapping GDP for GTP.
Upon glucagon binding, GCGR promotes the exchange of GDP for GTP on the alpha subunit of the heterotrimeric G-protein complex [QuickGO definition]. This exchange activates the G-alpha subunit, which then dissociates from the beta-gamma subunits and modulates downstream effectors such as adenylyl cyclase, leading to increased cAMP production. This signaling cascade is a hallmark of glucagon receptor activity and is targeted by therapeutic agonists and antagonists.
Downstream signaling and metabolic effects
In simple terms: The signal leads to changes in cell behavior, especially increased glucose production.
Activated G-alpha subunits stimulate adenylyl cyclase, raising intracellular cAMP and activating protein kinase A (PKA), which phosphorylates key metabolic enzymes. In hepatocytes, this promotes glycogenolysis and gluconeogenesis, increasing blood glucose. In the kidney, GCGR signaling influences renal function and systemic homeostasis. Dysregulation of this pathway is linked to hyperglycemia and metabolic disease.
Desensitization and arrestin-mediated regulation
In simple terms: The receptor is turned off and internalized after signaling.
Following activation, GCGR is phosphorylated by G-protein-coupled receptor kinases (GRKs), which recruit beta-arrestins. Arrestin binding sterically hinders further G-protein coupling and targets the receptor for internalization via clathrin-coated pits. Recent structural work has elucidated the tail engagement of arrestin at the glucagon receptor, providing mechanistic insight into this regulatory step. This process is critical for terminating glucagon receptor activity and preventing sustained signaling.
Key Genes Involved in GO:0004967 glucagon receptor activity
The following genes and proteins are directly involved in glucagon receptor activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCGR | Glucagon receptor; binds glucagon and activates G-proteins | Primary gene for GO:0004967; target of agonists/antagonists |
| GNAS | Encodes Gs-alpha subunit; mediates GDP/GTP exchange and adenylyl cyclase activation | Downstream effector of GCGR signaling [QuickGO definition] |
| GNB1 | G-protein beta subunit; part of heterotrimeric G-protein complex | Required for G-protein heterotrimer formation [QuickGO definition] |
| GNG2 | G-protein gamma subunit; part of heterotrimeric G-protein complex | Modulates G-protein signaling [QuickGO definition] |
| ADCY1 | Adenylyl cyclase; produces cAMP upon Gs activation | Downstream amplifier of glucagon signaling |
| PRKACA | cAMP-dependent protein kinase A catalytic subunit; phosphorylates metabolic enzymes | Mediates metabolic effects of glucagon |
| ARRB1 | Beta-arrestin 1; desensitizes GCGR and promotes internalization | Regulates receptor activity duration |
| ARRB2 | Beta-arrestin 2; desensitizes GCGR and promotes internalization | Regulates receptor activity duration |
| GRK2 | G-protein-coupled receptor kinase 2; phosphorylates activated GCGR | Initiates arrestin recruitment |
| GIPR | Glucose-dependent insulinotropic polypeptide receptor; co-targeted in dual agonists | Therapeutic synergy with GCGR |
| GLP1R | Glucagon-like peptide-1 receptor; co-targeted in dual/triple agonists | Therapeutic synergy with GCGR |
| PKA | Protein kinase A; downstream effector of cAMP | Mediates glucagon-induced metabolic changes |
| CREB1 | cAMP response element-binding protein; transcription factor activated by PKA | Regulates gluconeogenic gene expression |
| FOXO1 | Forkhead box O1; integrates insulin and glucagon signaling | Modulates hepatic glucose production |
| PCK1 | Phosphoenolpyruvate carboxykinase 1; rate-limiting gluconeogenic enzyme | Induced by glucagon signaling |
| G6PC | Glucose-6-phosphatase; catalyzes final step of gluconeogenesis | Induced by glucagon signaling |
| INSR | Insulin receptor; counter-regulates glucagon signaling | Context for metabolic disease models |
How Is glucagon receptor activity Regulated?
Glucagon receptor activity is regulated at multiple levels. Agonist binding is the primary trigger, but receptor desensitization is controlled by GRK-mediated phosphorylation and beta-arrestin recruitment, which uncouple the receptor from G-proteins and promote internalization. Additionally, the expression level of GCGR is modulated in disease states; for example, downregulation of kidney GCGR contributes to chronic kidney disease progression. Pharmacological regulation includes small-molecule antagonists and peptide agonists that either block or enhance glucagon receptor activity. Constitutive activity of GCGR variants has been observed in birds, leading to elevated blood glucose, highlighting the importance of intrinsic receptor regulation.
glucagon receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCGR | Type 2 diabetes, obesity | Liver-specific GCGR knockout mice; humanized GCGR knock-in mice |
| GCGR | Chronic kidney disease | Kidney-specific GCGR knockout mice |
| GCGR | Heart failure with preserved ejection fraction | GCGR antagonist treatment in HFpEF mouse models |
| GCGR | Avian hyperglycemia | Constitutively active GCGR knock-in in avian models |
| ARRB1/ARRB2 | Metabolic disease modulation | Arrestin knockout mice; point mutations in GCGR phosphorylation sites |
Diabetes and obesity
Glucagon receptor activity directly promotes hepatic glucose production, and excessive glucagon signaling contributes to hyperglycemia in diabetes. Dual and triple receptor agonists that engage GCGR alongside GIPR and GLP-1R have demonstrated clinical efficacy for glycemic control and weight loss. Mazdutide, a dual GLP-1/glucagon receptor agonist, received its first approval for obesity, underscoring the therapeutic relevance of modulating glucagon receptor activity.
Chronic kidney disease
Downregulation of the kidney glucagon receptor is essential for renal function and systemic homeostasis, and its loss contributes to chronic kidney disease progression. This highlights a tissue-specific role for glucagon receptor activity beyond the liver.
Heart failure with preserved ejection fraction
Glucagon receptor antagonism has been investigated as a therapeutic strategy for heart failure with preserved ejection fraction, suggesting that excessive glucagon receptor activity may contribute to cardiovascular pathophysiology.
Metabolic adaptation in birds
Constitutively active glucagon receptor drives high blood glucose in birds, providing an evolutionary perspective on the role of glucagon receptor activity in glucose regulation.
From glucagon receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GCGR loss affect hepatic glucose production? | Liver-specific GCGR knockout (Cre-lox) |
| Does a point mutation in GCGR alter G-protein coupling? | CRISPR point-mutation knock-in of GCGR variants |
| Can a tagged GCGR be used for trafficking studies? | Knock-in of fluorescent or epitope-tagged GCGR |
| Does GCGR overexpression drive hyperglycemia? | Transgenic or viral overexpression of GCGR in liver |
| What is the role of kidney GCGR in CKD? | Kidney-specific GCGR knockout |
| How does arrestin engagement regulate GCGR? | Arrestin knockout or point-mutant GCGR knock-in |
How to Study the glucagon receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cAMP assay | Intracellular cAMP levels | Measure GCGR agonist/antagonist activity |
| GTPgammaS binding | G-protein activation | Quantify GDP/GTP exchange [QuickGO definition] |
| Beta-arrestin recruitment | Arrestin translocation | Assess desensitization |
| CRISPR knockout | Gene function loss | Study GCGR role in metabolism |
| CRISPR knock-in | Specific mutations | Model constitutively active GCGR |
| RNA-seq | Transcriptional changes | Identify downstream targets |
| Cryo-EM | Receptor structure | Understand activation mechanism |
CRISPR knockout and knock-in models
CRISPR-Cas9 genome editing enables the generation of GCGR knockout cell lines and animal models to study loss-of-function phenotypes. Knock-in of specific point mutations (e.g., constitutively active variants) allows precise interrogation of glucagon receptor activity. These models are essential for causal inference in metabolic and cardiovascular research.
Biochemical signaling assays
cAMP accumulation assays, GTPgammaS binding, and beta-arrestin recruitment assays are standard methods to measure glucagon receptor activity. These assays can be used to test agonists and antagonists, such as dauricine, and to characterize mutant receptors.
Structural biology and imaging
Cryo-electron microscopy and X-ray crystallography have provided high-resolution structures of GCGR in complex with G-proteins and arrestins, revealing the molecular basis of receptor activation and regulation. Fluorescence microscopy can track receptor internalization and trafficking in live cells.
Transcriptomics and proteomics
RNA sequencing and proteomics can identify downstream transcriptional and signaling changes following modulation of glucagon receptor activity, uncovering novel effectors and biomarkers in metabolic tissues.
How CRISPR Can Be Used to Study GO:0004967 glucagon receptor activity
Knockout
CRISPR knockout of GCGR in cell lines or animal models abolishes glucagon receptor activity, allowing researchers to study its role in glucose homeostasis and disease. Liver-specific GCGR knockout mice are used to dissect hepatic glucose production.
Point Mutation
Point mutations in GCGR can mimic constitutively active or inactive states. For example, a constitutively active GCGR variant drives high blood glucose in birds, and CRISPR knock-in of such mutations can model hyperglycemia.
Knock-in
Knock-in of tagged GCGR (e.g., fluorescent protein) enables real-time imaging of receptor trafficking and arrestin engagement, providing insights into desensitization mechanisms.
Overexpression
Overexpression of GCGR in cell lines or tissues can amplify glucagon signaling, useful for studying downstream effects and for drug screening. Viral vectors or transgenic models are commonly used.
How EDITGENE Supports glucagon receptor activity Research
Researchers studying glucagon receptor activity-related genes often need to determine whether a candidate gene is causally involved in metabolic or cardiovascular phenotypes. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional studies of GCGR signaling.
Contact EDITGENE today to design your custom CRISPR model for glucagon receptor activity research.
Frequently Asked Questions About glucagon receptor activity
What is glucagon receptor activity?
Glucagon receptor activity (GO:0004967) is a molecular function where the glucagon receptor binds glucagon and activates an associated G-protein by promoting GDP-for-GTP exchange on the G-alpha subunit, transmitting a signal across the membrane [QuickGO definition].
What genes are involved in glucagon receptor activity?
The primary gene is GCGR, which encodes the glucagon receptor. Downstream genes include GNAS, GNB1, GNG2, ADCY1, PRKACA, and arrestins (ARRB1, ARRB2) [QuickGO definition].
What diseases are linked to glucagon receptor activity?
Dysregulated glucagon receptor activity is linked to type 2 diabetes, obesity, chronic kidney disease, and heart failure with preserved ejection fraction.
How is glucagon receptor activity regulated?
It is regulated by agonist binding, GRK-mediated phosphorylation, beta-arrestin recruitment, and receptor internalization.
What are the therapeutic implications of targeting glucagon receptor activity?
Dual and triple receptor agonists that engage GCGR improve glycemic control and weight loss, and GCGR antagonists are explored for heart failure.
What experimental models are used to study glucagon receptor activity?
CRISPR knockout, point-mutation knock-in, overexpression models, and animal models such as liver-specific GCGR knockout mice are commonly used.
What is the role of GCGR in the kidney?
Kidney GCGR downregulation contributes to chronic kidney disease, indicating a role in renal function and systemic homeostasis.
Can glucagon receptor activity be measured in vitro?
Yes, cAMP assays, GTPgammaS binding, and beta-arrestin recruitment assays are standard methods.
What is the structure of the glucagon receptor?
GCGR is a class B G-protein-coupled receptor with a large extracellular domain for glucagon binding and a seven-transmembrane domain for G-protein coupling.
How does arrestin regulate glucagon receptor activity?
Arrestin binds to phosphorylated GCGR, uncoupling it from G-proteins and promoting internalization, thus terminating signaling.
Conclusion
Glucagon receptor activity (GO:0004967) is a fundamental molecular function that mediates glucagon signaling and plays a critical role in glucose homeostasis and metabolic disease. Understanding its mechanism, regulation, and disease relevance is essential for developing targeted therapies. CRISPR-based models and biochemical assays provide powerful tools to dissect this activity, and EDITGENE offers comprehensive services to support such research.
References
- 1. Coskun T et al.. 2022. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metab 34(9):1234-1247.e9 PMID: 35985340
- 2. Katsi V et al.. 2025. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules 15(6) PMID: 40563436
- 3. Gao C et al.. 2024. Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction.. Circ Res 135(5):614-628 PMID: 39011638
- 4. Li L et al.. 2022. Antagonistic Effect and In Vitro Activity of Dauricine on Glucagon Receptor.. J Nat Prod 85(8):2035-2043 PMID: 35834753
- 5. Zhang C et al.. 2025. Constitutively active glucagon receptor drives high blood glucose in birds.. Nature 641(8065):1287-1297 PMID: 40031956
- 6. Shirley M. 2025. Mazdutide: First Approval.. Drugs 85(12):1621-1627 PMID: 41028652
- 7. Wang MY et al.. 2024. Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease.. Cell Metab 36(3):575-597.e7 PMID: 38237602
- 8. Chen K et al.. 2023. Tail engagement of arrestin at the glucagon receptor.. Nature 620(7975):904-910 PMID: 37558880
